Seyed Ahmad Ashrafi Sells 700 Shares of BioSyent (CVE:RX) Stock

BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi sold 700 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of C$16.00, for a total transaction of C$11,200.00. Following the sale, the director owned 30,361 shares in the company, valued at approximately C$485,776. The trade was a 2.25% decrease in their position.

Seyed Ahmad Ashrafi also recently made the following trade(s):

• On Wednesday, September 2nd, Seyed Ahmad Ashrafi sold 100 shares of BioSyent stock. The stock was sold at an average price of C$16.00, for a total transaction of C$1,600.00.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock. The shares were sold at an average price of C$14.65, for a total value of C$27,600.60.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 800 shares of BioSyent stock. The shares were sold at an average price of C$14.70, for a total value of C$11,760.00.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 600 shares of BioSyent stock. The shares were sold at an average price of C$14.50, for a total value of C$8,700.00.

BioSyent Stock Up 0.6%

Shares of BioSyent stock traded up C$0.09 on Friday, reaching C$15.97. The company’s stock had a trading volume of 4,234 shares, compared to its average volume of 7,986. The company has a market capitalization of C$180.60 million, a price-to-earnings ratio of 18.70 and a beta of 1.11. The firm’s fifty day simple moving average is C$14.97 and its two-hundred day simple moving average is C$14.77. BioSyent Inc. has a 52 week low of C$10.65 and a 52 week high of C$16.25. The company has a quick ratio of 6.91, a current ratio of 2.07 and a debt-to-equity ratio of 6.85.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.